| Name | Title | Contact Details |
|---|
Bacterin International, Inc. is a Belgrade, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
For nearly 30 years, Press Ganey`s mission has been to support health care providers in understanding and improving the entire patient experience. As a strategic business partner to more than 10,000 health care organizations across the country and across the continuum of care, we are the leader in helping create continuous, sustainable improvement. Headquartered in South Bend, Indiana, Press Ganey serves clients nationwide with locally based teams of associates to ensure strong client connections and relationships. As a result, Press Ganey is acutely aware of the challenges and opportunities unique to specific providers and their communities. Our associates are professionals, deeply rooted in health care and strongly committed to our clients` success. Whether it`s in the hospital, medical practice, ambulatory or home care setting, we partner with clients to create and sustain a high-performance environment to ultimately improve the patient experience. Our comprehensive suite of health care solutions helps clients meet their goals of improved quality, better care and lower costs. Press Ganey provides both ongoing advisory services and consulting in all phases of performance improvement. Our patient experience advisors are uniquely trained and skilled to identify areas of opportunity and help clients implement targeted improvement plans. Our consultants, whose health care experience is a true differentiator, work in partnership with organizations to identify and implement best practices across their operations. Simply put, we are vested in our clients` success, and dedicated to helping understand and improve every dimension of the patient experience.
Detroit Institute for Children is a Detroit, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.
Life Science Outsourcing Inc is a Brea, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.